<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04265040</url>
  </required_header>
  <id_info>
    <org_study_id>TORCH-Plus DZHK21</org_study_id>
    <nct_id>NCT04265040</nct_id>
  </id_info>
  <brief_title>DZHK TORCH-Plus is a Registry for Patients With Cardiomyopathies and Serves as Source for Cardiovascular Research Studies</brief_title>
  <acronym>TORCH-Plus</acronym>
  <official_title>TranslatiOnal Registry for CardiomyopatHies (TORCH) - Plus as Part of the German Centre for Cardiovascular Research (DZHK)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Heidelberg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Medicine Greifswald</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>German Heart Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Mannheim</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Schleswig-Holstein</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical University of Hannover</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Frankfurt</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Medical Center Mainz</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Medical Center Goettingen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Deutsches Herzzentrum Muenchen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Technische Universität München</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Munich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kerckhoff Klinik</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Heidelberg</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The DZHK TranslatiOnal Registry for CardiomyopatHies (DZHK TORCH) represents a unique&#xD;
      resource of clinical data and high quality biological samples to enable innovative clinical&#xD;
      and molecular studies on cardiomyopathies (CMP). As a multi-center German cardiomyopathy&#xD;
      registry, TORCH has been prospectively admitting patients since December 2014. 2,300 patients&#xD;
      were recruited as planned. Taken together, patient data showed that the prevalence of these&#xD;
      diseases is much higher in men than in women, atrial fibrillation is common in all forms of&#xD;
      CMPs as well as rare forms of disease indicate a higher risk and higher morbidity.&#xD;
&#xD;
      This DZHK TORCH register is now to be expanded with a second phase (DZHK TORCH-Plus). The&#xD;
      second phase DZHK TORCH-Plus consists of 4 main modules: 1. &quot;Clinical phenotyping, follow-up&#xD;
      &amp; biosampling&quot; 2. &quot;Genomics&quot;, 3. &quot;Inflammation&quot; and 4. &quot;Biomarker&quot;. The central aims are 1)&#xD;
      to significantly increase the number of probands (n = 4340) in order to better address the&#xD;
      different types of CMPs, especially patients with rare CMP forms such as LVNC and ARVC or&#xD;
      with probably molecularly explainable cardiomyopathies (familial DCM), 2) to prolong the&#xD;
      longitudinal with a further follow-up to achieve sufficient events and thereby derive&#xD;
      clinical recommendations for risk assessment, 3) to increase the number of probands with&#xD;
      state-of-the-art phenotyping, 4) to pinpoint the effect of myocardial inflammation, fibrosis,&#xD;
      gender and to determine or predict genotypes based for outcome, 5) to validate novel&#xD;
      biomarkers developed in other DZHK studies, and 6) to foster active cooperation with&#xD;
      international CMP registries and partners from industry.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 18, 2020</start_date>
  <completion_date type="Anticipated">December 2027</completion_date>
  <primary_completion_date type="Anticipated">December 2027</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>4 Years</target_duration>
  <primary_outcome>
    <measure>all-cause mortality</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">2040</enrollment>
  <condition>Non-ischemic Cardiomyopathy</condition>
  <condition>DCM - Dilated Cardiomyopathy</condition>
  <condition>HCM - Hypertrophic Cardiomyopathy</condition>
  <condition>HOCM - Hypertrophic Obstructive Cardiomyopathy</condition>
  <condition>Arrhythmogenic Right Ventricular Cardiomyopathy</condition>
  <condition>Left Ventricular Noncompaction Cardiomyopathy</condition>
  <condition>Amyloidosis</condition>
  <condition>Inflammatory Cardiomyopathy</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Primary care clinic&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Non-ischemic structural cardiomyopathies&#xD;
&#xD;
          -  Age ≥ 18 or ≤ 80 years&#xD;
&#xD;
          -  The patient is able to understand the declaration of consent and to sign it dated&#xD;
&#xD;
          -  At least one of the following diagnoses depending on the specific TORCH-&#xD;
&#xD;
        Plus inclusion / exclusion - SOP:&#xD;
&#xD;
        Dilated Cardiomyopathy (DCM)&#xD;
&#xD;
          -  family / genetic&#xD;
&#xD;
          -  inflammatory / persistent myocarditis&#xD;
&#xD;
          -  idiopathic (after exclusion secondary cause)&#xD;
&#xD;
          -  left sided systolic dysfunction (EF ≤ 45%)&#xD;
&#xD;
        Left ventricular hypertrophy&#xD;
&#xD;
          -  sarcomere hypertrophic cardiomoypathia (HCM, HOCM)&#xD;
&#xD;
          -  amyloid (AL: light chains, TTR: transthyretin, wild type)&#xD;
&#xD;
        Left ventricular non-compaction cardiomyopathy (LVNC)&#xD;
&#xD;
        Arrhythmogenic right ventricular cardiomyopathy (ARVC / D)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        The following exclusion criteria have been defined and must be taken from the TORCH-Plus&#xD;
        specific inclusion / exclusion - SOP in detail:&#xD;
&#xD;
          -  Age: &lt;18 years or&gt; 80 years&#xD;
&#xD;
          -  Patient has other (cardiac) previous illnesses:&#xD;
&#xD;
               -  uncontrollable arterial hypertension&#xD;
&#xD;
               -  primary pulmonary arterial hypertension&#xD;
&#xD;
               -  radiation therapy in the chest area&#xD;
&#xD;
               -  addiction (drug or alcohol abuse)&#xD;
&#xD;
               -  life expectancy &lt;1 year due to non-cardiological pre-existing conditions&#xD;
&#xD;
               -  significant heart valve disease&#xD;
&#xD;
               -  ischemic diseases and severe congenital heart diseases (including VSD, Fallot&#xD;
                  tetralogy, Ebstein anomaly)&#xD;
&#xD;
               -  chemotoxic cardiomyopathy&#xD;
&#xD;
               -  condition after myocarditis&#xD;
&#xD;
               -  combination of several traditional risk factors (e.g. hypertension and diabetes&#xD;
                  mellitus)&#xD;
&#xD;
               -  advanced chronic non-cardiac disease (e.g. chronic hepatitis or HIV)&#xD;
&#xD;
               -  Tachymyopathy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Farbod Sedaghat-Hamendani, Dr.</last_name>
    <phone>+496221/56-8676</phone>
    <email>Farbod.Sedaghat-Hamedani@med.uni-heidelberg.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Johannes Trebing, Dr.</last_name>
    <email>Johannes.Trebing@med.uni-heidelberg.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Heidelberg - Clinic of Cardiology, Angiology and Pneumology</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Wuerttemberg</state>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Farbod Sedaghat-Hamedani, Dr.</last_name>
      <phone>+496221568676</phone>
      <email>Farbod.Sedaghat-Hamedani@med.uni-heidelberg.de</email>
    </contact>
    <contact_backup>
      <last_name>Johannes Trebing, Dr.</last_name>
      <email>Johannes.Trebing@med.uni-heidelberg.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>February 7, 2020</study_first_submitted>
  <study_first_submitted_qc>February 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 11, 2020</study_first_posted>
  <last_update_submitted>December 11, 2020</last_update_submitted>
  <last_update_submitted_qc>December 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Heidelberg</investigator_affiliation>
    <investigator_full_name>Benjamin Meder</investigator_full_name>
    <investigator_title>Deputy Director - Clinic of Cardiology, Angiology and Pneumology</investigator_title>
  </responsible_party>
  <keyword>Cardiomyopathies, registry, data, biomaterial, genetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Cardiomyopathy, Hypertrophic</mesh_term>
    <mesh_term>Cardiomyopathy, Dilated</mesh_term>
    <mesh_term>Arrhythmogenic Right Ventricular Dysplasia</mesh_term>
    <mesh_term>Amyloidosis</mesh_term>
    <mesh_term>Hypertrophy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

